This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES Europe: Oligonucleotide and Peptide Therapeutics
11-13 November 2025
Congress Center BaselBasel, Switzerland

Seb Caille, PhD
Senior Director at Avidity Biosciences
Speaker

Profile

Seb is the Senior Director of Oligonucleotide Development at Avidity Biosciences, where he leads a team focused on development, characterization, and validation of processes to manufacture late-stage assets such as Del-desiran, Del-brax, and Del-zota. Prior to joining Avidity, Seb was a Scientific Director at Amgen, where he led teams managing the development of processes to prepare small molecules, oligonucleotides, glycosides, and peptides, in all phases of CMC development. His teams delivered processes for the manufacture of Omecamtiv Mecarbil, Sotorasib, and Olpasiran. Seb is the author of forty-seven refereed publications throughout his career and the recipient of an ACS Mid-Career Investigator Award (2024). Seb is an active member of IQ and EPOC working groups.

Agenda Sessions

  • Commercialization, Manufacture, and Control of Antibody-Oligonucleotides Conjugates

    10:45